Our Twitter handle, @AcceleronPharma, provides an exciting opportunity to connect and interact with individuals and organizations interested in our company. We intend to use Twitter to share company news and announcements, provide corporate information and live updates from scientific, medical, and investor conferences, and participate in important community outreach and disease awareness efforts.
It is our goal to interact with as many Twitter users as possible when appropriate, but please note we may not be able to reply individually to all messages received via @AcceleronPharma. Tweets from members of the public do not reflect the views of Acceleron Pharma and we reserve the right to block or mute users for any reason, including posting inappropriate or offensive material, at our sole discretion, with or without notice. If we choose to follow a Twitter account, or a user follows @AcceleronPharma, this action is not an endorsement of the content of those other accounts or that member of the public post on our account or elsewhere.
@AcceleronPharma is not a forum to report any medical adverse events or reactions or complaints about our investigational products. If you are participating in a clinical study and believe you have experienced an adverse event or side effect related to an Acceleron Pharma investigational product, please contact your study doctor immediately. You can also visit the FDA safety information and adverse reporting program online. If you post a direct Tweet to @AcceleronPharma with information about an adverse event or side effect, please note we may be required to contact you for additional information to comply with regulatory guidelines.
The healthcare sector is a highly regulated industry. Due to these regulations, we may be unable to engage in discussions about therapeutic candidates and will not offer medical advice using the @AcceleronPharma Twitter handle. If you have a question or comment related to our therapeutic candidates, email us at socialmedia@XLRN.com.